

July 19, 2007

vasopharm's trauma compound VAS203 successfully completes first-in-man study

Wuerzburg, Germany – July 19, 2007

vasopharm GmbH, a pharmaceutical company dedicated to the discovery and development of novel therapeutics for the treatment of cerebro- and cardiovascular diseases, announced today the successful completion of the first-in-man study with its NOS inhibitor VAS203.

The study revealed that plasma concentrations were reached at much lower doses than expected from animal experiments. In this dose range VAS203 was very well tolerated and safe. The single dose administration study will now be followed by a multiple dose study which is currently under preparation.

Facts about vasopharm:

vasopharm is a pharmaceutical company dedicated to the discovery and development of novel therapeutics for the treatment of cerebro- and cardiovascular diseases and their consequences. The company is focused on the development of therapeutics which permits modulating the bioavailability of biological NO, by addressing the entire NO/cGMP signal cascade and its functional counterpart NOX. vasopharm's drug candidate VAS203 represents a completely new class of NOS modulators targeting cerebral vessels and cerebral tissue, thus preventing life threatening rises in intracranial pressure.
